Capillary electrophoretic investigation of the enantioselective metabolism of propafenone by human cytochrome P-450SUPERSOMES: Evidence for atypical kinetics by CYP2D6 and CYP3A4

被引:20
作者
Afshar, Minoo [1 ]
Thormann, Wolfgang [1 ]
机构
[1] Univ Bern, Dept Clin Pharmacol, CH-3010 Bern, Switzerland
关键词
5-Hydroxy-propafenone; in vitro metabolism; N-despropyl-propafenone; stereoselective metabolism; sulfated beta-cycloclextrin;
D O I
10.1002/elps.200500664
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
An enantioselective CE method was used to identify the ability of CYP450 enzymes and their stereoselectivity in catalyzing the transformation of propafenone (PPF) to 5-hydroxy-propafenone (5OH-PPF) and N-despropyl-propafenone (NOR-PPF). Using in vitro incubations with single CYP450 enzymes (SUPERSOMES), 5OH-PPF is shown to be selectively produced by CYP2D6 and N-dealkylation is demonstrated to be mediated by CYP2D6, CYP3A4, CYP1A2, and CYP1A1. For the elucidation of kinetic aspects of the metabolism with CYP2D6 and CYP3A4, incubations with individual PPF enantiomers and racemic PPF were investigated. With the exception of the dealkylation in presence of R-PPF only, which can be described by the Michaelis-Menten model, all CYP2D6-induced reactions were found to follow autoactivation kinetics. For CYP3A4, all NOR-PPF enantiomer formation rates as function of PPF enantiomer concentration were determined to follow substrate inhibition kinetics. The formation of NOR-PPF by the different enzymes is stereoselective and is reduced significantly when racemic PPF is incubated. Clearance values obtained for CYP3A4 dealkylation are stereoselective whereas those of CYP2D6 hydroxylation are not. This paper reports the first investigation of the PPF hydroxylation and dealkylation kinetics by the CYP2D6 enzyme and represents the first report in which enantioselective CE data provide the complete in vitro kinetics of metabolic steps of a drug.
引用
收藏
页码:1526 / 1536
页数:11
相关论文
共 38 条
[1]   Validated capillary electrophoresis assay for the simultaneous enantioselective determination of propafenone and its major metabolites in biological samples [J].
Afshar, Minoo ;
Thormann, Wolfgang .
ELECTROPHORESIS, 2006, 27 (08) :1517-1525
[2]  
Anzenbacherova Eva, 2003, Biomedical Papers (Olomouc), V147, P155
[3]   Implications of the allosteric kinetics of cytochrome P450s [J].
Atkins, WM .
DRUG DISCOVERY TODAY, 2004, 9 (11) :478-484
[4]  
BOTSCH S, 1993, MOL PHARMACOL, V43, P120
[5]   An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons [J].
Brandon, EFA ;
Raap, CD ;
Meijerman, I ;
Beijnen, JH ;
Schellens, JHM .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2003, 189 (03) :233-246
[6]  
DOLLERY C, 1999, THERAPEUTIC DRUGS, P243
[7]   PROPAFENONE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC USE IN THE TREATMENT OF ARRHYTHMIAS [J].
HARRON, WG ;
BROGDEN, RN .
DRUGS, 1987, 34 (06) :617-647
[8]   Effect of selective serotonin reuptake inhibitors on the oxidative metabolism of propafenone:: In vitro studies using human liver microsomes [J].
Hemeryck, A ;
De Vriendt, C ;
Belpaire, FM .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2000, 20 (04) :428-434
[9]   CLINICAL PHARMACOKINETICS OF PROPAFENONE [J].
HII, JTY ;
DUFF, HJ ;
BURGESS, ED .
CLINICAL PHARMACOKINETICS, 1991, 21 (01) :1-10
[10]  
Houston JB, 2000, DRUG METAB DISPOS, V28, P246